Back to Search
Start Over
The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease
- Source :
- Alzheimer's Research & Therapy, Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-11 (2020)
- Publication Year :
- 2020
- Publisher :
- BioMed Central, 2020.
-
Abstract
- Background To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzheimer’s disease mutation (E280A) in Presenilin-1, who are genetically determined to develop early-onset dementia, from matched non-carriers. We also sought to examine whether LAS-FNAME performance is associated with amyloid-β and regional tau burden in mutation carriers. Methods A total of 35 cognitively intact mutation carriers (age range 26–41), 19 symptomatic carriers, and 48 matched non-carriers (age range 27–44) completed a neuropsychological assessment including the LAS-FNAME. A subset of participants (31 carriers [12 symptomatic] and 35 non-carriers) traveled from Colombia to Boston to undergo positron emission tomography (PET) using Pittsburgh compound B to measure mean cortical amyloid-β and flortaucipir for regional tau. ANOVA analyses and Spearman correlations were used to examine group differences and relationships among LAS-FNAME performance and amyloid-β and tau accumulation. Results Compared to non-carriers, cognitively intact mutation carriers had lower scores on the LAS-FNAME Total Scores (p = .040). Across all carriers (including symptomatic carriers), higher levels of amyloid-β (r = − .436, p = .018) and regional tau in the entorhinal (r = − .394, p = .031) and inferior temporal cortex (r = − .563, p = .001) were associated with lower LAS-FNAME Total Scores. Conclusions Performance on the LAS-FNAME differentiated between cognitively intact mutation carriers from non-carriers and was associated with greater amyloid and tau burden when examining all carriers. Findings suggest that the LAS-FNAME is sensitive to early clinical and pathological changes and can potentially help track disease progression in Spanish-speaking individuals.
- Subjects :
- Adult
0301 basic medicine
Oncology
medicine.medical_specialty
Neurology
Cognitive Neuroscience
Disease
lcsh:RC346-429
lcsh:RC321-571
Imaging
03 medical and health sciences
chemistry.chemical_compound
Cognition
0302 clinical medicine
Alzheimer Disease
Memory
Neuropsychology
Internal medicine
Presenilin-1
medicine
Humans
Dementia
Neuropsychological assessment
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
Pathological
lcsh:Neurology. Diseases of the nervous system
Temporal cortex
medicine.diagnostic_test
business.industry
Research
Associative memory
medicine.disease
Latin America
030104 developmental biology
Autosomal dominant Alzheimer’s disease
PET
chemistry
Positron-Emission Tomography
Neurology (clinical)
Pittsburgh compound B
business
Alzheimer’s disease
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 17589193
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Alzheimer's Research & Therapy
- Accession number :
- edsair.doi.dedup.....e04ccc9d953109b80572f4f60660a30e